Vaped Phenanthrene

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age21+
SponsorUniversity of Minnesota

About this trial

Some people who used to smoke cigarettes continue to be at higher risk of developing lung cancer, even years after quitting. This study will look to see if a specific chemical, phenanthrene, is broken down in the lungs of former smokers through more harmful pathways than never-smokers. If former smokers break down chemicals that enter their lungs through more harmful pathways this might be putting them at higher risk for developing lung cancer even though they quit smoking. This information may help find better ways to prevent or treat cancer in the future.

This study is under an IND, but the drug is not being studied; instead, it is being used as a marker for drug metabolism.

Eligibility criteria

Qualifiers

> 21 years of age

In good physical & mental health

In stable physical & mental health

Have tried vaping

Disqualifiers

Has any respiratory disease (ex - asthma, COPD, etc...)

Has/had high blood pressure

Has/had liver disease

Has/had cancer

Trial design

Treatments tested in this trial

  • D10-phenanthrene

Treatment groups

100 Participants
are divided into 1 treatment group

Sponsors and collaborators